Phyllis Matter | Obituary | The Daily Item
Phyllis Matter passed away. This is the full obituary where you can share condolences and memories. Published in the The Daily Item on 2023-12-07.
Source: dailyitem.com
June Bray News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from June Bray. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In June Bray Today - Breaking & Trending Today
Echo Lake Capital Offers to Acquire Quince Therapeutics, Inc.
Offers $1.60 per share in cashOffer represents 90% premium to yesterday's closing priceStock currently trades below its current cash and investments balance of $2.55 per shareCompany also has other assets
Source: finanznachrichten.de
Cortexyme Appoints June Bray to its Board of Directors
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company focused on rare and degenerative diseases, today announced the appointment of June Bray, a pharmaceutical industry veteran and global drug development and regulatory process expert, to the company...
Source: pharmiweb.com
Travecta Therapeutics Announces Broad Expansion of its Executive, Governance and Scientific Advisory Leadership Teams
/PRNewswire/ -- Travecta Therapeutics, Pte Ltd., a preclinical stage biopharmaceutical company pioneering a portfolio of product candidates engineered to cross...
Source: prnewswire.com
BioXcel Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
Published: Mar 11, 2021 New Drug Application (“NDA”) submitted to the U.S. Food and Drug Administration (“FDA”) for BXCL501 for the acute treatment of schizophrenia and bipolar disorder related agitation TRANQUILITY achieved primary and secondary endpoints with both doses of BXCL501; End of Phase 2 meeting with the FDA planned for Q2 2021 RELEASE trial on track to report topline results in Q1 2021 Topline results from two ongoing trials with BXCL701 in aggressive forms of prostate cancer and advanced solid tumors are expected in mid-2021 Company to host conference call today at ...
Source: biospace.com